Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.133.91.171
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Ophthalmology

Susac syndrome requires sustained, long term immunotherapy

Posted on

Most patients with Susac syndrome, a rare autoimmune condition that can affect the blood vessels in the retina leading to vision loss, require sustained therapy of multiple immune-suppressive, according to data presented at the 2020 AAO Virtual Meeting.

In addition to vision loss, Susac syndrome is characterized by brain disease and hearing loss.

In this retrospective review, 22 patients with Susac syndrome who had at least 12 months of follow-up were included.

-Advertisement-
-Advertisement-

Artery occlusions and segmental vascular hyperflourescence were identified by fundus exam in 15 and 11 patients, respectively.

Twelve patients underwent treatment including intravenous immunoglobulin (IVIG) and an antimetabolite, whereas 10 patients with severe disease underwent treatment including IVIG, an antimetabolite, or cyclophosphamide and rituximab.

During the follow-up period, 13 patients experienced flares with a total of 28 episodes, 11 of which were CNS related and 17 retina related.

Patients who were able to successfully stop taking immunotherapy included 6 with milder disease and 1 with severe disease.

Reference

Arepalli S, et al. Long-Term Cerebral and Retinal Outcomes of Immunosuppression in Susac Syndrome. Presented at: 2020 AAO Virtual.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-